V

Vistin Pharma ASA
OSE:VISTN

Watchlist Manager
Vistin Pharma ASA
OSE:VISTN
Watchlist
Price: 24 NOK 1.69% Market Closed
Market Cap: 1.1B NOK

Vistin Pharma ASA
Investor Relations

Vistin Pharma ASA engages in the manufacture and sale of metformin products. The company is headquartered in Oslo, Oslo. The company went IPO on 2015-06-10. The company was created as a result of spin-off of Weifa AS. The company specializes in manufacture of Active Pharmaceutical Ingredients (API) and Solid Dosage Forms. Its products portfolio is comprised of Metformin, Pholcodine and Codeine Phosphate, among others. The firm's products are sold domestically and abroad, including markets in Asia, America, Africa and Europe.

Show more
Loading

Earnings Calls

2024 Q3
Jun 6, 2024
Show Transcript
Previous
Next
Duckhorn's Q3 Performance Driven by Strong Margins and Expense Management
2024 Q3
Jun 6, 2024

Duckhorn delivered a strong Q3 with net sales of $92.5 million, up 1.4%, despite challenging market conditions. Adjusted EBITDA rose 5.3% year-over-year to $37.7 million, improving margins by 150 basis points to 40.8%. The company benefitted from robust gross margins and active cost controls. The acquisition of Sonoma-Cutrer is expected to add $16 million in Q4, contributing to a revised full-year sales forecast of $398-408 million, with an adjusted EBITDA range of $146-150 million. Management remains optimistic about long-term growth, driven by distributor realignment and consumer preference for premium wines.

Show Full Analysis

Management

Mr. Magnus Tolleshaug
CEO, Chief Commercial Officer & Commercial Director
No Bio Available
Mr. Alexander Karlsen
Chief Financial Officer
No Bio Available
Mr. Vegard Heggem
Chief Operating Officer
No Bio Available
Eivind Egeli
Director of Technical Service & Sales
No Bio Available

Contacts

Address
OSLO
Oslo
Ostensjoveien 27
Contacts
+4735984200.0